Hypothermic Machine Perfusion Preservation of the DCD Kidney: Machine Effects by Lindell, Susanne L. et al.
Virginia Commonwealth University
VCU Scholars Compass
Surgery Publications Dept. of Surgery
2013
Hypothermic Machine Perfusion Preservation of
the DCD Kidney: Machine Effects
Susanne L. Lindell
Virginia Commonwealth University, slindell@mcvh-vcu.edu
Heather Muir
Virginia Commonwealth University
John Brassil
Virginia Commonwealth University
Martin J. Mangino
Virginia Commonwealth University, mjmangino@vcu.edu
Follow this and additional works at: http://scholarscompass.vcu.edu/surgery_pubs
Copyright © 2013 Susanne L. Lindell et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original
work is properly cited.
This Article is brought to you for free and open access by the Dept. of Surgery at VCU Scholars Compass. It has been accepted for inclusion in Surgery
Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/surgery_pubs/7
Hindawi Publishing Corporation
Journal of Transplantation
Volume 2013, Article ID 802618, 7 pages
http://dx.doi.org/10.1155/2013/802618
Research Article
Hypothermic Machine Perfusion Preservation of
the DCD Kidney: Machine Effects
Susanne L. Lindell,1 Heather Muir,1 John Brassil,2 and Martin J. Mangino1,3,4
1 Departments of Surgery, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond,
VA 23298-0454, USA
2 Functional Circulation, Northbrook, IL 60062, USA
3 Emergency Medicine, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, VA 23298-0454, USA
4Physiology and Biophysics, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond,
VA 23298-0454, USA
Correspondence should be addressed to Martin J. Mangino; mjmangino@vcu.edu
Received 10 July 2013; Accepted 9 September 2013
Academic Editor: Parmjeet Randhawa
Copyright © 2013 Susanne L. Lindell et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Purpose. Kidneys from DCD donors represent a significant pool, but preservation problems exist. The study objective was to test
the importance of machine type for hypothermic preservation of DCD kidneys.Methods. Adult Beagle dog kidneys underwent 45
minutes of warm in situ ischemia followed by hypothermic perfusion for 24 hours (Belzer-MPS Solution) on either anORS LifePort
or a Waters RM3 using standard perfusion protocols. Kidneys were then autotransplanted, and renal function was assessed over
7 days following contralateral nephrectomy. Results. Renal vascular resistance was not different between the two pumps. After 24
hours, the oxygen partial pressure and oxygen delivery in the LifePort perfusate were significantly lower than those in the RM3 but
not low enough to change lactate production. TheLifePort ran significantly colder than RM3 (2∘ versus 5∘C). The arterial pressure
waveform of the RM3 was qualitatively different from the waveform of the LifePort. Preservation injury after transplantation was
not different between the devices. When the LifePort was changed to nonpulsatile flow, kidneys displayed significantly greater
preservation injury compared to RM3. Conclusions. Both LifePort and RM3 can be used for hypothermic machine perfusion
preservation of DCD kidneys with equal outcomes as long as the duty cycle remains pulsatile.
1. Introduction
Renal transplantation continues to be the treatment of choice
for patients with end stage renal disease. Currently, over
91,000 renal patients are wait listed to receive a kidney
transplant while last year only 17% were transplanted [1].
While the wait list for kidneys seems to grow geometrically,
the rate of transplantation grows linearly, leaving centers to
look for new ways to expand the donor pool.
One source of kidney donors that have gained con-
siderable attention over the last decade is Donation after
Cardiac Death (DCD). The pool of controlled DCD kidneys
is small since only about 10% of kidneys come from this
category [2]. The pool for uncontrolled DCD kidney donors,
however, is potentially huge. It has been estimated that
of the 335,000 cardiac deaths that occurred in 2006, at
least 22,000 (7%) may meet the criteria for uncontrolled
DCD donation [3]. This has the conservative potential of
unleashing 44,000 kidneys per year into the donor pool,
which could seriously alleviate the donor shortage since the
total number of all deceased donor kidney transplants in
the USA in all of 2011 was only 11,043. Furthermore, the
technical and logistic ability to use these kidneys is high in
large cities that share both a major transplant center and a
busy Emergency Medicine/Trauma service, thus making the
theoretical implications for using uncontrolled DCD kidneys
more realistic. However, the problemwith using uncontrolled
DCD kidneys is the necessary exposure of warm ischemia to
the grafts before harvest and preservation. While the effects
of 30–90 minutes of warm renal ischemia per se produce
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measured reperfusion injury to the kidney at transplantation,
the addition of inevitable periods of hypothermia from
traditional organ preservation, nomatter how brief, produces
potentiating injury that exceeds the sum of both factors
combined [4, 5]. This typically results in very high incidence
of delayed graft function (DGF) following transplantation
[6].
To mitigate against heightened preservation injury in
DCD kidneys, hypothermic pulsatile machine perfusion
preservation is utilized. The theoretical benefits of perfusion
of DCD kidneys have been recently demonstrated con-
clusively. Canine kidneys with 60 minutes of prior warm
ischemia were 100% viable when perfused with UW-based
solutions on a Belzer pulsatile perfusionmachine for 24 hours
compared to 40% viable when cold stored in UW solution for
the same time [4]. Similar results have recently been observed
in clinical studies. Moers demonstrated an overall superiority
of perfusion preservation, relative to simple cold storage,
of kidneys in a paired prospective large clinical trial. Graft
viability of paired donor kidneys was significantly improved
when one kidneywasmachine perfused compared to the cold
stored contralateral control kidney after 1 year [7] or 3 years
after transplantation [8]. In the 3-year study [8], the machine
perfusion effect was dramatically amplified in a subgroup
of patients that experienced initial delayed graft function.
Finally, hypothermic machine perfusion has recently been
demonstrated to be superior to cold storage in preservation
of kidneys from DCD donors [9]. This further supports the
utility of using machine perfusion in reanimating injured
kidneys from DCD donors. By significantly reducing the
incidence of DGF in this donor group [9], hypothermic
machine perfusion should also improve the long term half-
life of these grafts.
Today, hypothermic machine perfusion of kidneys in
the transplant clinic typically utilizes one of two types
of perfusion machines: the Waters (Waters Medical Sys-
tems) RM3 or the ORS (Organ Recovery Systems) LifePort.
Although both machines are designed to perfuse kidneys
with cold crystalloid preservatives under pulsatile conditions,
many engineering and performance differences raise the
possibility that their performance under DCD conditions
is also different. Such differences include perfusate oxy-
genation, perfusate operational temperatures, motor duty
cycle, arterial waveform differences, and differences in how
they are typically used by clinicians (operational protocols).
Characterizing outcomes between these two devices in a
prospective controlled pre-clinical setting was the objective
of this study since it has never been done. The hypothesis
was that kidneys from DCD donors would perform better
after preservation on the Waters RM3 compared to the ORS
LifePort because of the availability of oxygen and the pulsatile
duty cycle of the pump.
2. Materials and Methods
2.1. Materials and Methods. Adult Beagle dogs were anes-
thetized with propofol (10–17mg/kg, I.V. bolus) followed by
intubation and isoflurane inhalation anesthesia at 1–3% with
50% oxygen. All animal studies were conducted under a
protocol approved by the VCU IACUC. After anesthesia, a
midline incision was made to expose the left kidney.The ves-
sels and ureter were isolated and skeletonized. Both the renal
artery and vein were ligated with 0-silk ties for 45 minutes
to induce warm renal ischemia. After the ischemic period,
the kidney was removed and the renal artery was quickly
flushed with about 100mL of cold saline containing Heparin
(5,000U/L). After organ donation, the animals were closed
and recovered from surgery using standard techniques. The
kidneys were immediately placed on a perfusion machine for
24 hours. Each kidney was randomized to either the RM3 or
the LifePort, and 8 dogs were used for each treatment arm. In
a subgroup of 4 additional dogs, the perfusate was delivered
without pulsations (at 30mmHg) on the LifePort. Each group
was perfused with cold Belzer MPS solution according to the
following protocols that are typically used in the clinic.
2.1.1. LifePort. The kidneys were perfused from the start at
a mean pressure setting of 30mmHg in pulsatile mode.
Four additional dogs were perfused in nonpulsatile mode.
The LifePort actively maintains this pressure by continuously
adjusting the flow rate by feedback.
2.1.2. RM3. The kidneys were perfused at an initial flow that
produced a peak systolic pressure of 45mmHg by slowly
raising the flow rate over 10 minutes. Then the flow rate was
continuously adjusted tomaintain this target systolic pressure
over the next 4 hours. After 4 hours, the pump flow rate was
held constant for the next 24 hours and the perfusion pressure
was allowed to change in step with changes in resistance.
The LifePort was cooled by an internal heat exchanger
using melting ice while sitting on the lab bench while the
RM3 was cooled by placing the entire unit in a cold room,
which was actively maintained at 6–8∘C. The RM3 unit was
oxygenated by sweeping air over the membrane oxygenator
at about 2–4 L/min while the LifePort had no active or
passive method of perfusate oxygenation. Performance of the
kidneys on the pump was monitored by recording perfu-
sion pressure, perfusate flow, vascular resistance, perfusate
temperature, pH, electrolytes, and pO
2
during the perfusion
period. After 24 hours of perfusion preservation, kidneys
were removed from the pump and autotransplanted into the
original donor animal as previously described [4]. At the time
of autotransplantation, the right contralateral kidney was
removed. No post-operative immunosuppressive medica-
tions were required or given. Renal function and preservation
injury were assessed each post-operative day by measuring
renal function by a daily venous blooddraw. Serumcreatinine
was measured in daily venous blood samples for 7 days using
a Vet Scan HM5 (Abaxis, Union City, CA) clinical chemistry
analyzer. After the 7-day observation period, the animalswere
euthanized with Euthasol.
2.2. Experimental Design. The first study was designed to
test if a difference existed in the outcomes of DCD kidneys
perfused on a LifePort or an RM3 machine. Eight dogs each
donated one kidney to the ORS and one kidney to theWaters
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pump group in a paired experimental design. Seven dogs
in each group completed the study as two animals were
euthanized 3 days after surgery due to severe giardiasis and
their data were not included in the study. A third group was
used to test the effects of pulsatility per se on preservation of
DCDkidneys by using the LifePort in constant pressuremode
(30mmHg mean) with no pulsations and comparing those
results to the group run on the LifePort in pulsatile mode
(30mmHg mean).
2.3. Statistical Analysis. All data were tested for normality of
distribution and found to be normal. Descriptive statistics
(mean, standard deviation, count, and standard error of the
mean) were determined with statistical software (Graph-
Pad, V4.1). Differences in the means between groups were
analyzed by GraphPad software using an unpaired 𝑡-test
(2 groups) or one-way ANOVA with Dunnett’s multiple
comparison test (>2 groups) using an 𝛼 = 0.05. Fisher’s Exact
test was used for survival ratios.
3. Results
Machine perfusion parameters over the 24-hour hypother-
mic perfusion period for kidneys in both machine groups
were similar. The mean perfusion pressure was significantly
higher by about 6mmHg in the Waters group compared to
the ORS group (Figure 1(a)). The perfusate flows were also
proportionally higher in the Waters perfused kidneys such
that the vascular resistance in both groups was the same over
the 24-hour perfusion preservation period (Figure 1(b)).
Metabolic characteristics during machine perfusion were
also compared (Figures 1(c)–1(f)). The temperature of opera-
tion of the Waters machine was significantly higher than the
ORS LifePort (5.5∘C versus 2.2∘C, resp.). While the metabolic
demand was slightly higher in the warmer Waters machine,
the delivery of oxygen was significantly higher than LifePort
too. Specifically, the perfusate pO
2
started off identical in
both machines at the start of perfusion preservation, but 24
hours later, the perfusate from the Waters machine had a
significantly higher pO
2
. Since the arterial inflow rates were
similar, the higher arterial inflow pO
2
in Waters translates
into a significantly higher delivery of oxygen to the kidney
(DVO
2
) compared to the ORS LifePort. In spite of the lower
inflow oxygen tension in the LifePort at the end of perfusion,
the lactate concentrations in the perfusate were not different
(Figure 1(f)). Perfusate electrolyte and pH were the same in
both groups.
An analysis of the arterial pressure waveform of both
machines revealed some significant differences. While both
devices produce a pulsatilewaveform, there are some interest-
ing qualitative differences. A pressure transducer connected
to the arterial side of the perfusion pump recorded real-
time changes in arterial pressure in both Waters and ORS
device (Figure 2). Both machines produced pulsatile flow but
the LifePort pressure waveform was clearly wider, shorter,
and exhibiting a smaller pulse pressure, relative to the RM3
arterial pressure waveform.
Posttransplant renal function after 24 hours of perfusion
preservation was assessed for 7 days after transplantation
to index the degree of renal preservation injury suffered by
each group of kidneys from DCD donors. True DGF cannot
be assessed in this model, so the model is calibrated to
cause maximal renal injury without causing death from renal
failure. The results shown in Figure 3(a) indicate that the
serum creatinine values after transplantation were essentially
identical in both machine groups. The injury produced by
this model, relative to a non-DCD injury, and the efficacy
of machine perfusion, relative to cold storage, has been
previously characterized in detail by our group [4]. While
there was no difference in outcomes between the two perfu-
sion machines, the presence of a pulsatile pump duty cycle
was important. Specifically, pulsatile perfusion significantly
improved outcomes of DCD kidneys after transplantation
since a significant potentiation of preservation injury was
observed in kidneys fromDCDdonors that were perfused on
a LifePort under constant pressure conditions (nonpulsatile
mode), relative to perfusion on the LifePort in pulsatile mode
(Figure 3(b)).
4. Discussion
Perfusion preservation of kidneys is becoming more com-
mon, especially since the rates of ECD and DCD donation
have significantly increased. This upward pressure has led
to more careful analysis of available machine perfusion
devices regarding their differences, similarities, and capa-
bilities under today’s donation conditions. The two most
popular devices used internationally today are the Waters
RM3 and the ORS LifePort. These devices have significant
differences in design and operation, but this study has clearly
demonstrated that both machines perform equally for the
hypothermic perfusion preservation of DCD kidneys, as
indexed by the evaluation of posttransplant renal function
in a proven dog renal autotransplant model. This model was
used to accurately test UW solution 20 years ago and it
correctly predicted the clinical response for human organs so
its use for this study is appropriate and valid for predicting the
clinical effects of these two machines under simulated DCD
conditions.
The “Mini Belzer Unit” kidney perfusion machine was
the first portable kidney perfusion machine used by the
University of Wisconsin for routine preservation of kidneys
for transplantation beginning in 1972 and used up until 2008.
The commercial device later produced by Waters copied the
general design and perfusion drive of the Belzer Machine,
which consisted of an electric motor driven pump that
cyclically squeezed perfusate out of a compressible bladder
between two moving plates. These pumps contained one-
way valves, which mimicked the heart and produced truly
physiological pulsatile arterial pressure waveforms that look
remarkably like an arterial pressure waveform in a human.
These waveforms even have a clearly identifiable dicrotic
notch, representing the closure of the outflow valve during
the end of pump systole. The success of the Belzer machines
and the similar Waters machines have been attributed to
this specific pump duty cycle and the physiological pressure
waveforms that they produce in addition to active oxygena-
tion of the perfusate. However, this study shows similar
4 Journal of Transplantation
0 1 2 3 4 24
25
30
35
40
45
Perfusion time (hours)
(m
m
H
g)
M
ea
n 
pe
rf
us
io
n 
pr
es
su
re
Waters RM3
ORS LifePort
(a)
0 60 120 180 240 1440
1.0
1.5
2.0
2.5
Waters RM3
ORS LifePort
Time (minutes)
Va
sc
ul
ar
 re
sis
ta
nc
e
(m
m
H
g/
m
L/
m
in
)
(24hours) 
(b)
∗
Waters RM3
LifePort ORS
8
6
4
2
0
Te
m
pe
ra
tu
re
 (∘
C)
(c)
0
50
100
150
200
250
Initial End
LifePort ORS
Waters RM3
Pe
rf
us
at
e
PO
2
(m
m
H
g)
∗
(d)
∗
Waters RM3
LifePort ORS
0.4
0.3
0.2
0.1
0.0
D
VO
2
(m
L/
m
in
)
(e)
La
ct
at
e (
m
M
)
Waters RM3
LifePort ORS
0.8
0.6
0.4
0.2
0.0
(f)
Figure 1: Machine perfusion characteristics of DCD kidneys pumped on a Waters RM3 or an ORS LifePort device for 24 hours. Mean
perfusion pressure (a), vascular resistance during perfusion (b), average perfusate temperature (c), initial and end perfusate pO
2
values (d),
end of perfusion delivery of oxygen (DVO
2
) (e), and end of perfusion perfusate lactate concentrations (f) values are mean ± S.D., ∗𝑃 < 0.05
relative to LifePort, 𝑛 = 8 per group.
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Figure 2: Samples of arterial pressure waveforms from a Waters RM3 and an ORS Lifeport during perfusion preservation.
outcomes with the ORS LifePort, which produced a more
attenuated pulsatile flow and pressure waveform and has
no means of perfusate oxygenation. The LifePort arterial
pressure waveform has a significantly smaller pulse pressure
and few physiological characteristics like a dicrotic notch or a
diastolic decay. In constant pressuremode (no pulsatility), the
ORS LifePort performs significantly worse compared to the
pulsatile mode under near identical conditions (Figure 3(b)).
Thus, it appears from these studies that pulsatile flow per se
is an important and necessary attribute for good perfusion
preservation of DCD kidneys but the magnitude or quality of
the pulsations is less important.
The utility of machine perfusion preservation for DCD
kidneys was notmeasured in this study but was assumed.The
goal of this study was to determine which of two commonly
used clinical machines were more useful for preserving DCD
kidneys but not if perfusion is better than cold storage. The
usefulness of hypothermicmachine perfusion per se forDCD
kidneys over simple cold storage was first demonstrated by
Lindell et al., in a preclinical study in 2005 [4] and later for
DCDpatients [9] and for non-DCDpatients [7, 8].Therefore,
only a simple experimental design consisting ofDCDkidneys
perfused on either a LifePort or an RM3 was needed to
complete the objectives of the study.
The need for oxygenation of the kidney perfusate in clin-
ical devices has been debated. Some perfusionists claim that
oxygenation of the perfusate is necessary, either from room
air or oxygen facilitated by an extracorporeal membrane oxy-
genator or from passive equilibration with the atmosphere.
Many also believe that this is critical for successfully preserv-
ing injured kidneys fromDCD donors.The ORS LifePort has
no provision for either active or passive oxygenation of the
perfusate since it was designed for portability. However, it
performs as an RM3 or a Belzer machine, which both have
active oxygenation. This study suggests that physiological
levels of oxygenation in the perfusate are not necessary for
goodperfusion preservation ofDCDkidneys since therewere
no differences between the two machines, which had signif-
icantly different perfusate pO
2
levels at the end of perfusion.
However, the ORS was run at a cooler temperature, which
reduced oxygen demand compared to the RM3. Neither
pump in this study had a limiting oxygen delivery since the
ends of perfusion lactate levels were the same in each group
and were low, suggesting that anaerobic glucose fermentation
was not occurring secondary to inadequate oxygen delivery.
This even occurred in the ORS LifePort that had perfusate
pO
2
levels around 30mmHg after 24 hours of perfusion
preservation. Thus, at profound hypothermic temperatures,
active or passive perfusate oxygenation is not necessary, even
for DCD kidneys. While the Waters RM3 has a lot of oxygen
delivery reserve capacity because of its active oxygen transfer
properties, the ORS LifePort may be close to “running on
empty” after 24 hours. Therefore, longer perfusion times
past 24 hours for DCD kidneys are not recommended in
the LifePort without some form of passive or active oxygen
transfer. These features were avoided in the LifePort design
to produce portability and to decrease heat transfer, which are
important attributes of the LifePort. Since human kidneys are
much larger and have higher absolute oxygen consumption
rates under these conditions, relative to our small Beagle dog
kidneys, there should be more concern of limiting oxygen
delivery when the device is used in humans for more than
24 hours.
Sufficient oxygen delivery to kidneys perfused at 4–6∘C
with crystalloid preservation solutions is not an issue since
the slow metabolic rate of the kidneys at such profound
hypothermic temperatures reduces the metabolic demand
to about 3% of baseline rates [10]. At this low level of
metabolism, slow flow rates of water based solutions, either
equilibrated with room air or oxygen (RM3) or not equili-
brated at all (LifePort), produce sufficient oxygen delivery in
both machines. The lack of lactate accumulation under these
conditions proves this point. However, if higher perfusion
temperatures or longer duration of perfusion is attempted
with the LifePort, then the DVO
2
may need to increase,
either through higher flow rates, a higher O
2
carrying
capacity (carriers), higher O
2
concentration of the solution,
or combinations of these. An additional source of oxygen
will be required to facilitate oxygen transfer to the solution
phase.Therefore, the LifePort would need to adapt some form
of active or passive oxygen delivery in order to meet these
demands whereas the RM3 already has some of this capacity.
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Figure 3: Daily serum creatinine values after kidney autotransplan-
tation after DCD donation. Kidneys were perfused for 24 hours
using the LifePort (Open Squares) or the RM3 (SolidCircles). Values
aremean± S.D. and represent 8 dogs per group (Figure 3(a)). Similar
data (Figure 3(b)) are shown for a LifePort operated under either
constant pressure (nonpulsatile flow) or pulsatile flow conditions
(both at 30mmHg). The values are statistically different between
the first 3 corresponding post-operative days. The survival in the
pulsatile and nonpulsatile groups were 100% (8/8) and 50% (2/4),
respectively (𝑃 = 0.09).
The new version of LifePort has an external oxygenation
option.
The current studymodeled clinicalDCDkidney donation
by inducing in situ warm renal ischemia before recovery and
preservation in large animals, which does not completely
model the conditions in clinical DCD donors. The question
is whether any modeling shortcomings represent significant
deviation from the clinical condition and whether these
differences prevent a correct analysis of the results. The
ischemia induced in situ in this study, while producing a clin-
ically relevant degree of warm ischemia, is produced under
conditions that differ in clinical DCD recovery. Specifically,
the physiological, biochemical, and immunological changes
associated with trauma and agonal cardiac death in DCD
patients before organ recovery are missing in our animal
model and may influence preservation injury. However, the
model was the same for both groups, so any missing effect
would be controlled and treated equally between the two
groups. Therefore, any real differences between the model
and real clinical experiences should not alter the conclusions
of the study, which were based on the relative comparisons
between the twomachine perfusion groups. Finally, any phys-
iological, biochemical, hormonal, or immunological adjust-
ments to cardiac death that were missing from the current
DCDmodel may not have produced a measurable difference
in the outcomes anyway since similar adjustments, due to the
agonal phase after explosive brain death, are not observable
in the same large animal kidney transplant model [11].
Another potential problemwith this model is the severity
of the induced renal failure. Specifically, uncontrolled DCD
kidneys in the clinic will often cause DGF and require renal
replacement therapy with dialysis until the graft begins to
regain function over the coming weeks. Then, the graft may
be at higher risk for developing chronic allograft nephropathy
(CAN)months later. Our model does not induce renal injury
severe enough to cause clinical DGF since the animals cannot
be placed on dialysis. Therefore, we calibrate the severity
to not cause animal death and rely on renal graft function
after transplantation as a measured outcome of preservation
injury. Furthermore, since our model is an autotransplant,
we miss any long-term nephropathy because the allogeneic
immunological background is lost, which is probably essen-
tial for the development of CAN [12]. However, this model is
still useful since renal autograft function measured after the
first week of transplantation is proportional and predictive of
preservation injury in the graft [13].
In conclusion, this study has determined that DCD
kidneys can be effectively machine perfused for 24 hours
on either an ORS LifePort or a Waters RM3 with equal
outcomes, provided that the LifePort is used in pulsatile
mode. Each device has both positive and limiting attributes
that must be considered, especially when using them under
unconventional conditions.
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